高级检索
当前位置: 首页 > 详情页

Ligustilide promotes apoptosis of cancer-associated fibroblasts via the TLR4 pathways.

文献详情

资源类型:
Pubmed体系:
机构: [a]Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China [b]Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China [c]School of Basic Medical Sciences of Southwest Medical University, Luzhou, Sichuan, China [d]College of Life Science, University of the Chinese Academy of Sciences, Beijing, China [e]Infinitus Chinese Herbal Immunity Research Centre, Infinitus China Company Ltd, Guangzhou, China
出处:
ISSN:

关键词: Ligustilide Tumor microenvironment Fibroblast Apoptosis Cell cycle

摘要:
The goal of this research was to study the selective pro-apoptotic effect of ligustilide on prostate-cancer-associated fibroblast in the tumor microenvironment and the related molecular mechanisms. The effects of ligustilide on cancer-associated fibroblasts (CAFs) and normal fibroblasts (NFs) isolated from the prostate were determined by MTT assay. Flow cytometry and cellular immunofluorescence were used to detect the effects of ligustilide on the cell cycle and apoptosis. Western blotting was used to detect the expression of apoptosis-related proteins after the action of ligustilide on CAFs. In the investigation, ligustilide had a selective pro-apoptotic effect on prostate-CAFs. After ligustilide treatment, the proportion of CAFs in the G2-M phase of the cell cycle increased, and the expression of apoptosis-related proteins (p-P53, Bcl-2, Caspase9 and Cytochrome C) changed. Ligustilide blocks the CAF cell cycle and induces the apoptosis of CAFs. Copyright © 2019 Elsevier Ltd. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 1 区 毒理学 2 区 食品科技
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 食品科技 3 区 毒理学
第一作者:
第一作者机构: [a]Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China [b]Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China [c]School of Basic Medical Sciences of Southwest Medical University, Luzhou, Sichuan, China
共同第一作者:
通讯作者:
通讯机构: [a]Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China [b]Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China [c]School of Basic Medical Sciences of Southwest Medical University, Luzhou, Sichuan, China [d]College of Life Science, University of the Chinese Academy of Sciences, Beijing, China [*1]Institute of Biophysics, Chinese Academy of Sciences, No. 15 Datun Road, Chaoyang Area, Beijing City, China. [*2]Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. [*3]Institute of Science and Technology, Southwest Medical University, Luzhou, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号